Adaptive Biotechnologies (ADPT) Gross Margin (2018 - 2026)

Adaptive Biotechnologies has disclosed Gross Margin across 9 years of filings, most recently posting 71.82% for Q2 2026.

• In Q2 2026, Gross Margin rose 239.0% year-over-year to 71.82%; the TTM figure through Jun 2026 stood at 75.57% (up 953.0% YoY), while the FY2025 annual figure was 74.24%, up 1451.0% from the prior year.
• Gross Margin came in at 71.82% for Q2 2026 at Adaptive Biotechnologies, down from 73.6% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 80.68% in Q3 2025 to a low of 48.98% in Q3 2023.
• Average Gross Margin over 5 years is 65.01%, with a median of 66.73% recorded in 2025.
• Year-over-year, Gross Margin tumbled 1985 bps in 2023 and surged 1657 bps in 2025.
• Over 5 years, Gross Margin stood at 69.95% in 2022, then fell by 18 bps to 57.16% in 2023, then advanced by 8 bps to 61.98% in 2024, then climbed by 20 bps to 74.58% in 2025, then declined by 4 bps to 71.82% in 2026.
• Per Business Quant data, the three most recent Gross Margin figures were 71.82% in Q2 2026, 73.6% in Q1 2026, and 74.58% in Q4 2025.